What this means
This program lets some eligible people get an experimental drug before it is approved. A doctor must decide if the possible benefit is greater than the risk.
Plain-English summary written by an AI model from the registry listing.
- Status
- Available
- Who can join
- See eligibility
- Where
- Not listed
The science
- Registered title
- Expanded Access to ABBV-CLS-484
- Trial ID
- NCT06188975 ↗
- Phase
- Not applicable
- Study type
- expanded_access
- Conditions
- Advanced Solid Tumor Cancer
- What is tested
- DRUG: ABBV-CLS-484
- Sponsor
- Calico Life Sciences LLC
- Ages
- No minimum to no maximum
- Dates
- First posted Jan 3, 2024 · updated Jan 3, 2024
Registry summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-CLS-484 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.